Zogenix logo 19.01.22

UCB is buying biopharmaceutical company Zogenix for $1.9 billion. Under the terms of the agreement, UCB will make a tender offer to buy all of Zogenix's outstanding shares at $26 per share plus $2 per share, subject to approval of FINTEPLA, the drug to treat Lennox-Gasto syndrome, by December 31, 2023. The transaction is expected to close in Q2 2022.